Drug Profile
RF 1010
Latest Information Update: 19 Jan 2011
Price :
$50
*
At a glance
- Originator SuperGen
- Class Antianaemics; Growth factors
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia; Neutropenia
Most Recent Events
- 19 Jan 2011 Discontinued - Phase-II for Anaemia in USA (unspecified route)
- 19 Jan 2011 Discontinued - Phase-II for Neutropenia in USA (unspecified route)
- 03 Aug 2001 RF 1010 is available for licensing http://www.supergen.com/